Journey Medical (DERM) Aktievy
Journey Medical Corporation, ett läkemedelsbolag i kommersiell fas som fokuserar på utveckling och kommersialisering av läkemedelsprodukter för behandling av dermatologiska tillstånd i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 6/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
DERM Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Journey Medical Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$6.13 |
| 52 veckors högsta | US$9.56 |
| 52 veckors lägsta | US$4.31 |
| Beta | 1.1 |
| 1 månads förändring | -3.24% |
| 3 månaders förändring | -13.97% |
| 1 års förändring | -2.93% |
| 3 års förändring | 194.47% |
| 5 års förändring | n/a |
| Förändring sedan börsintroduktionen | -35.53% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 03
DERM: Expanded Access Progress Will Support Future Parent Group Value
Narrative Update on Journey Medical The analyst price target for Journey Medical has been adjusted from $13.25 to $13.50, as analysts factor in updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples influenced in part by recent Street research attention on both Journey Medical and its parent Fortress Biotech. Analyst Commentary Recent Street research around Journey Medical and Fortress Biotech has given investors more context on how analysts are thinking about value, execution, and growth for Journey Medical within the broader group structure.Uppdatering av berättelse • Apr 27
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.Uppdatering av berättelse • Apr 12
DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.Recent updates
Uppdatering av berättelse • Jun 03
DERM: Expanded Access Progress Will Support Future Parent Group Value
Narrative Update on Journey Medical The analyst price target for Journey Medical has been adjusted from $13.25 to $13.50, as analysts factor in updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples influenced in part by recent Street research attention on both Journey Medical and its parent Fortress Biotech. Analyst Commentary Recent Street research around Journey Medical and Fortress Biotech has given investors more context on how analysts are thinking about value, execution, and growth for Journey Medical within the broader group structure.Uppdatering av berättelse • Apr 27
DERM: Expanded Access And Execution Progress Will Support Future Upside
Narrative Update: Journey Medical Analyst Price Target Shift Analysts have lifted their price target on Journey Medical by $1 to $13.25, citing updated research that supports a higher valuation for the shares. Analyst Commentary Analysts highlighting the move to a US$13.25 price target are framing it as a recalibration based on refreshed research rather than a wholesale shift in the story.Uppdatering av berättelse • Apr 12
DERM: At The Market Liquidity And Margin Progress Will Support Future Upside
Analysts have raised their price target on Journey Medical by $1 to $13.25, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E to support the new view. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$13.25 price target as better aligned with their updated fair value work, suggesting the prior target did not fully reflect their assumptions on earnings power and risk.
Ny berättelse • Apr 10
Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology treatments, with Emrosi as its flagship oral therapy for inflammatory rosacea lesions. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 28
DERM: At The Market Offering And Margin Progress Will Drive Future Upside
Analysts have adjusted their price target for Journey Medical to $13.25 from $13.50, citing updated views on revenue growth, profit margins, and the stock's future P/E multiple as reflected in recent Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as reflecting confidence that recent revenue trends and cost controls can support the revised P/E assumption used in their models.
Ny berättelse • Mar 26
Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside
Catalysts About Journey Medical Journey Medical focuses on commercializing prescription dermatology products, including Emrosi for rosacea, in the U.S. market. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 11
DERM: At The Market Equity Offering Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Journey Medical filed a follow-on equity offering for its common stock, signaling plans to raise additional capital through the equity market (Key Developments).Uppdatering av berättelse • Feb 25
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside Potential
Analysts have maintained their price target for Journey Medical at $13.50, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E for the company. What's in the News Journey Medical filed a follow on equity offering for its common stock as an at the market offering, giving the company the option to issue new shares into the market over time (Key Developments).Uppdatering av berättelse • Feb 10
DERM: Phase 1 Rosacea Microbiome Safety Will Drive Future Upside
Analysts have maintained their price target on Journey Medical at US$13.50, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions supporting this stable view. What's in the News Journey Medical filed a follow-on equity offering for its common stock as an at-the-market offering, indicating potential future issuance of additional shares (Key Developments).Uppdatering av berättelse • Jan 27
DERM: Phase 1 Rosacea Microbiome Safety Will Support Future Upside
Analysts have reaffirmed their price target on Journey Medical at US$13.50, citing unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their view steady. What's in the News Journey Medical filed a follow-on equity offering for its common stock, structured as an at-the-market offering.Analysartikel • Jan 14
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Uppdatering av berättelse • Jan 12
DERM: Phase 3 Rosacea Efficacy And Microbiome Safety Will Drive Upside
Analysts have maintained their price target for Journey Medical at US$13.50. This steady view reflects unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E.Uppdatering av berättelse • Dec 27
DERM: Phase 3 Rosacea Data And Microbiome Safety Will Support Further Upside
Analysts have modestly reiterated their outlook on Journey Medical, maintaining a price target of $13.50 per share as slight tweaks to the discount rate, revenue growth assumptions, profit margin, and future P E estimates leave their valuation framework effectively unchanged. What's in the News Phase 1 trial results for DFD-29, marketed as Emrosi, showed no detectable impact on skin, gastrointestinal, or vaginal microflora over 16 weeks and confirmed the therapy was well tolerated in healthy adults, supporting its use in moderate to severe rosacea (Key Developments).Uppdatering av berättelse • Dec 12
DERM: Phase 3 Rosacea Efficacy And Safety Will Likely Support Further Upside
Analysts have modestly reiterated their confidence in Journey Medical, maintaining their price target at 13.50 dollars. Unchanged near term revenue growth, profitability expectations, and valuation multiples continue to support the current fair value outlook.Uppdatering av berättelse • Nov 28
DERM: Recent Trial Success Will Likely Drive Shares Toward Upside Potential
Analysts have revised their price target for Journey Medical, maintaining it at $13.50 per share. Updates to projected profit margin and future valuation metrics prompted a reassessment of the company's growth outlook.Uppdatering av berättelse • Nov 14
DERM: Improved Margins and Clinical Results Are Expected to Drive Shares Higher
Analysts have raised their price target for Journey Medical from $11.80 to $13.50. They cite improved profit margin expectations despite slightly adjusted forecasts for revenue growth and discount rates.Analysartikel • Aug 15
US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
NasdaqCM:DERM 1 Year Share Price vs Fair Value Explore Journey Medical's Fair Values from the Community and select...Uppdatering av berättelse • Aug 15
Emrosi Launch Will Expand Rosacea Treatment Options
Journey Medical’s sharply improved net profit margin and lower future P/E ratio signal enhanced profitability and valuation appeal, driving the consensus analyst price target up from $10.50 to $11.50. What's in the News Pharmacy benefit coverage for Emrosi™ increased to 65% of US commercial lives, up from 29% in May.Analysartikel • Aug 12
Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Apr 01
Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ny berättelse • Mar 30
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.Analysartikel • Mar 25
A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Analysartikel • Feb 06
Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jan 11
Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Unfortunately for some shareholders, the Journey Medical Corporation ( NASDAQ:DERM ) share price has dived 26% in the...Analysartikel • Oct 03
Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Journey Medical Corporation ( NASDAQ:DERM ) shares have had a really impressive month, gaining 31% after a shaky period...Analysartikel • Sep 14
Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • May 06
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Mar 11
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
To the annoyance of some shareholders, Journey Medical Corporation ( NASDAQ:DERM ) shares are down a considerable 31...Analysartikel • Jan 18
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Journey Medical Corporation ( NASDAQ:DERM ) shares have retraced a considerable 33% in the last month, reversing a fair...Analysartikel • Nov 10
Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Journey Medical Corporation ( NASDAQ:DERM ) shares have continued their recent momentum with a 26% gain in the last...Aktieägarnas avkastning
| DERM | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | -0.9% | -0.5% | 2.2% |
| 1Y | -2.9% | 35.1% | 24.8% |
Avkastning vs industri: DERM presterade sämre än US Pharmaceuticals branschen som gav 35.1 % under det senaste året.
Avkastning vs Marknaden: DERM presterade sämre än US marknaden som gav 24.8 % under det senaste året.
Prisvolatilitet
| DERM volatility | |
|---|---|
| DERM Average Weekly Movement | 12.4% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: DERM s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: DERM s veckovolatilitet ( 12% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2014 | 58 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation är ett läkemedelsbolag i kommersiell fas som fokuserar på utveckling och kommersialisering av läkemedelsprodukter för behandling av dermatologiska tillstånd i USA. Bolagets marknadsförda produkter inkluderar Qbrexza, en medicinerad tygduk för behandling av primär axillär hyperhidros; Accutane, ett oralt isotretinoinläkemedel för behandling av svår nodulär akne; och Amzeeq, en topikal formulering av minocyklin för behandling av inflammatoriska lesioner av icke-nodulär måttlig till svår akne vulgaris. Företaget tillhandahåller också Zilxi, en topikal minocyklinbehandling för inflammatoriska lesioner av rosacea; Emrosi för behandling av inflammatoriska lesioner av rosacea; Exelderm kräm och lösning för behandling av svampinfektioner i huden; och Targadox, ett oralt doxycyklinläkemedel för tilläggsbehandling av svår akne, samt Luxamend, en vattenbaserad emulsion som ger en fuktig läkningsmiljö för ytliga sår, mindre skärsår eller skrapsår, hudsår, donationsställen, första och andra gradens brännskador, inklusive solbränna, och strålningsdermatit.
Journey Medical Corporation Sammanfattning av grunderna
| DERM grundläggande statistik | |
|---|---|
| Börsvärde | US$174.57m |
| Vinst(TTM) | -US$9.59m |
| Intäkter(TTM) | US$64.68m |
2.6x
P/S-förhållande-17.6x
P/E-förhållandeÄr DERM övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| DERM resultaträkning (TTM) | |
|---|---|
| Intäkter | US$64.68m |
| Kostnad för intäkter | US$22.35m |
| Bruttovinst | US$42.33m |
| Övriga kostnader | US$51.92m |
| Intäkter | -US$9.59m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.35 |
| Bruttomarginal | 65.44% |
| Nettovinstmarginal | -14.82% |
| Skuld/egenkapitalförhållande | 82.3% |
Hur har DERM utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/16 23:30 |
| Aktiekurs vid dagens slut | 2026/06/16 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Journey Medical Corporation bevakas av 5 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |